Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mainstreaming genetic testing of cancer predisposition genes.

Literature DB >> 25099850

Mainstreaming genetic testing of cancer predisposition genes.

Nazneen Rahman¹.

Abstract

Entities: Chemical Disease Gene Species

Keywords: BRCA1; BRCA2; Cancer predisposition genes; gene testing; next-generation sequencing

Mesh：

Year: 2014 PMID： 25099850 PMCID： PMC4312836 DOI： 10.7861/clinmedicine.14-4-436

Source DB: PubMed Journal: Clin Med (Lond) ISSN： 1470-2118 Impact factor: 2.659

× No keyword cloud information.

18 in total

Review 1. The inherited genetics of ovarian and endometrial cancer.

Authors: Simon A Gayther; Paul D P Pharoah
Journal: Curr Opin Genet Dev Date: 2010-04-24 Impact factor: 5.578

2. Next-generation DNA sequencing.

Authors: Jay Shendure; Hanlee Ji
Journal: Nat Biotechnol Date: 2008-10 Impact factor: 54.908

Review 3. RB1 gene mutations in retinoblastoma.

Authors: D R Lohmann
Journal: Hum Mutat Date: 1999 Impact factor: 4.878

Review 4. Familial adenomatous polyposis: The practical applications of clinical and molecular screening.

Authors: Paul Rozen; Finlay Macrae
Journal: Fam Cancer Date: 2006 Impact factor: 2.375

Review 5. Exploring the genomes of cancer cells: progress and promise.

Authors: Michael R Stratton
Journal: Science Date: 2011-03-25 Impact factor: 47.728

6. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Authors: Rossella Elisei; Cristina Romei; Barbara Cosci; Laura Agate; Valeria Bottici; Eleonora Molinaro; Mariangela Sculli; Paolo Miccoli; Fulvio Basolo; Lucia Grasso; Furio Pacini; Aldo Pinchera
Journal: J Clin Endocrinol Metab Date: 2007-09-25 Impact factor: 5.958

7. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.

Authors: Ingrid Slade; Chiara Bacchelli; Helen Davies; Anne Murray; Fatemeh Abbaszadeh; Sandra Hanks; Rita Barfoot; Amos Burke; Julia Chisholm; Martin Hewitt; Helen Jenkinson; Derek King; Bruce Morland; Barry Pizer; Katrina Prescott; Anand Saggar; Lucy Side; Heidi Traunecker; Sucheta Vaidya; Paul Ward; P Andrew Futreal; Gordan Vujanic; Andrew G Nicholson; Neil Sebire; Clare Turnbull; John R Priest; Kathryn Pritchard-Jones; Richard Houlston; Charles Stiller; Michael R Stratton; Jenny Douglas; Nazneen Rahman
Journal: J Med Genet Date: 2011-01-25 Impact factor: 6.318

8. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

Authors: Tomasz Byrski; Rebecca Dent; Pawel Blecharz; Malgorzata Foszczynska-Kloda; Jacek Gronwald; Tomasz Huzarski; Cezary Cybulski; Elzbieta Marczyk; Robert Chrzan; Andrea Eisen; Jan Lubinski; Steven A Narod
Journal: Breast Cancer Res Date: 2012-07-20 Impact factor: 6.466

9. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

Authors: Nicholas C Turner; Andrew N J Tutt
Journal: Breast Cancer Res Date: 2012-11-13 Impact factor: 6.466

10. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors: Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal: N Engl J Med Date: 2009-06-24 Impact factor: 91.245

26 in total

1. An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients.

Authors: Richard Baird; Ian Banks; David Cameron; John Chester; Helena Earl; Mark Flannagan; Adam Januszewski; Richard Kennedy; Sarah Payne; Emlyn Samuel; Hannah Taylor; Roshan Agarwal; Samreen Ahmed; Caroline Archer; Ruth Board; Judith Carser; Ellen Copson; David Cunningham; Rob Coleman; Adam Dangoor; Graham Dark; Diana Eccles; Chris Gallagher; Adam Glaser; Richard Griffiths; Geoff Hall; Marcia Hall; Danielle Harari; Michael Hawkins; Mark Hill; Peter Johnson; Alison Jones; Tania Kalsi; Eleni Karapanagiotou; Zoe Kemp; Janine Mansi; Ernie Marshall; Alex Mitchell; Maung Moe; Caroline Michie; Richard Neal; Tom Newsom-Davis; Alison Norton; Richard Osborne; Gargi Patel; John Radford; Alistair Ring; Emily Shaw; Rod Skinner; Dan Stark; Sam Turnbull; Galina Velikova; Jeff White; Alison Young; Johnathan Joffe; Peter Selby
Journal: Ecancermedicalscience Date: 2016-01-05

Review 2. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors: Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal: Signal Transduct Target Ther Date: 2020-01-03

3. Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.

Authors: Shamini Selvarajah; Kasmintan A Schrader; Michael P Kolinsky; Ricardo A Rendon; Soufiane El Hallani; Neil E Fleshner; Sebastien J Hotte; Justin Lorentz; Karen Panabaker; Renée Perrier; Frédéric Pouliot; Alan Spatz; Stephen Yip; Kim N Chi
Journal: Can Urol Assoc J Date: 2022-10 Impact factor: 2.052

Mainstreaming genetic testing of cancer predisposition genes.

Review 1. The inherited genetics of ovarian and endometrial cancer.

2. Next-generation DNA sequencing.

Review 3. RB1 gene mutations in retinoblastoma.

Review 4. Familial adenomatous polyposis: The practical applications of clinical and molecular screening.

Review 5. Exploring the genomes of cancer cells: progress and promise.

6. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

7. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.

8. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

9. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

10. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

1. An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients.

Review 2. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

3. Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.

Review 4. CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

5. The integration of BRCA testing into oncology clinics.

Review 6. Genetic causes of cancer predisposition in children and adolescents.

7. Genetic counselors and Genomic Counseling in the United Kingdom.

8. Using family history forms in pediatric oncology to identify patients for genetic assessment.

9. CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting.

10. Development of cancer genetic services in the UK: A national consultation.